Home > Insider Trading > Filing (0001225208-18-005098)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
78003	Pfizer Inc	PFE	Pharmaceutical Preparations (2834)	135315170

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1508517	H Charles Hill	Pfizer Inc.-Corp. Secretary 235 East 42Nd St. New York NY 10017	Executive Vice President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-02-28	101,872	$27.37	207,942	No	4	M	Direct
Common Stock	Disposition	2018-02-28	1,100	$36.84	206,842	No	4	S	Direct
Common Stock	Disposition	2018-02-28	3,200	$36.85	203,642	No	4	S	Direct
Common Stock	Disposition	2018-02-28	5,400	$36.82	198,242	No	4	S	Direct
Common Stock	Disposition	2018-02-28	17,079	$36.83	181,163	No	4	S	Direct
Common Stock	Disposition	2018-02-28	19,606	$36.31	161,557	No	4	F	Direct
Common Stock	Disposition	2018-02-28	61,836	$35.70	99,721	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	F	Direct
No	4	F	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Appreciation Rights	Disposition	2018-02-28	101,872	$0.00	101,872	$27.37

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2018-02-28	2018-02-28	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	11,414	Indirect	By Rule 16b-3 Plan

Footnotes

The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon).
The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.